WellSpan Home
Banner _Screen

Oncology Services

Treatment Studies

The York Cancer Center strives to bring the most current cancer therapies available to our community, with respect to treatment, symptom management, and prevention. We continue to collaborate in a large number of National Cancer Institute and industry-sanctioned cooperative group trials. These collaborations have allowed us the opportunity to help bring some cancer treatments to our community that would normally be available only at larger centers or universities.

Our research team continually works to provide the community with a variety of treatment trials. The research team is a dedicated group of professionals who work in conjunction with physicians, nurses and patients to facilitate enrollment in clinical trials, provide protocol therapy and detail collection of research data, which is then submitted to the statistical centers.

Below is a list of the cancer treatment clinical trials that are currently available to our patients in the community. To learn more about these studies, talk to your physician or the York Cancer Center.

NRG-BN001 - Open ACC and YCC

Brain

Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma

Record Created: 2014-10-16 10:21:02

A011202

Breast

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Record Created: 2015-12-31 09:49:53

Are Memory Changes Precipitated by Endocrine Therapy Treatment in Breast Cancer Patients Previously Treated with Chemotherapy

Breast

Are Memory Changes Precipitated by Endocrine Therapy Treatment in Breast Cancer Patients Previously Treated with Chemotherapy

Record Created: 2011-07-11 11:39:08

NRG-BR003

Breast

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Record Created: 2015-08-11 14:30:30

NSABP B-51

Breast

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Record Created: 2013-04-17 12:58:05

NSABP B-55

Breast

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Muti-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Record Created: 2015-04-15 13:09:55

PBI 3.0 - Open @ York Only

Breast

Multi-Institutional Randomized Trial of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with ER Negative Early Stage Breast Cancer (PBI 3.0)

Record Created: 2014-02-12 15:11:23

SWOG S1207

Breast

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of EVEROLIMUS in Patients with High-Risk Hormone Receptor-Positive AND HER2/neu Negative Breast Cancer. “e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.”

Record Created: 2013-10-08 10:03:41

York Cancer Center Patient Registry

Breast

York Cancer Center Patient Registry: A Study to Compile Information on the Efficacy of High Dose Rate (HDR) Brachytherapy in Providing Radiation Therapy to Breast Cancer Patients

Record Created: 2006-04-03 17:04:28

GOG 0238

GYN

A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus

Record Created: 2015-03-11 16:19:48

GOG-0225

GYN

Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Peritoneal Cancer Progression-Free Survival?

Record Created: 2014-08-13 13:37:50

GOG-0277

GYN

A Phase III Randomized Trial of Gemcitabine (NSC#613327) Plus Docetaxel (NSC#628503) Followed by Doxorubicin (NSC#123127) Versus Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma

Record Created: 2014-11-10 10:24:18

NRG-GY002

GYN

A Phase II Evaluation of Nivolumab, a Fully Human Antibody against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer

Record Created: 2015-06-18 14:01:19

NRG-GY005 - Pending Activation

GYN

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer (COCOS)

Record Created: 2016-03-22 08:54:26

NRG-GY006

GYN

A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, II, IIIB or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

Record Created: 2016-02-17 13:52:50

PCYC-1134M

Leukemia

informCLL: A Disease Registry for Patients with Chronic Lymphocytic Leukemia

Record Created: 2015-12-31 09:51:21

A081105

Lung

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Facto Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Record Created: 2015-12-31 09:43:42

A151216 - ALCEHMIST

Lung

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

Record Created: 2015-12-31 09:41:45

CALGB C30610/RTOG 0538

Lung

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

Record Created: 2008-04-23 14:13:40

E4512

Lung

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Record Created: 2015-12-31 09:45:41

EA5142 - pending activation

Lung

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Record Created: 2016-06-13 10:54:15

NRG-CC003 - Open York & GB

Lung

Randomized Phase II/III Trial of Prophylactic Crania Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

Record Created: 2015-12-31 09:47:36

SWOG S1400

Lung

S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

Record Created: 2014-07-29 13:04:26

SWOG S1403

Lung

"A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)"

Record Created: 2015-05-07 09:41:41

ECOG E1412

Lymphoma

Randomized Phase II open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Record Created: 2013-08-19 12:33:19

S1404

Melanoma

A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma."

Record Created: 2015-12-15 10:14:49

ECOG E1A11

Multiple Myeloma

Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MantenANCE in Patients with Newly DIagnosed Sympotmatic Multiple Myeloma (ENDURANCE)

Record Created: 2013-11-26 08:53:17

A031201

Prostate

Phase III Trial of Enzalutamide (NSC #766085) versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

Record Created: 2014-01-23 09:08:17

RTOG 0924 - QOL closed to accrual

Prostate

Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Record Created: 2011-08-04 15:26:29

ECOG- ACRIN EAY131 Sub-Study B

Solid Tumor/Lymphoma

Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations

Record Created: 2015-08-18 15:06:28

ECOG- ACRIN EAY131 Sub-Study C1

Solid Tumor/Lymphoma

Crizotinib in Patients with Tumors with MET Amplification

Record Created: 2016-06-08 11:20:19

ECOG- ACRIN EAY131 Sub-Study C2

Solid Tumor/Lymphoma

Crizotinib in Patients with Tumors with MET Exon 14 Deletion

Record Created: 2016-06-08 11:21:24

ECOG- ACRIN EAY131 Sub-Study E

Solid Tumor/Lymphoma

Testing AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR

Record Created: 2015-08-18 15:07:56

ECOG- ACRIN EAY131 Sub-Study F

Solid Tumor/Lymphoma

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations

Record Created: 2015-06-18 13:56:23

ECOG- ACRIN EAY131 Sub-Study G

Solid Tumor/Lymphoma

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer)

Record Created: 2015-06-18 13:58:18

ECOG- ACRIN EAY131 Sub-Study H

Solid Tumor/Lymphoma

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)

Record Created: 2015-06-18 13:59:27

ECOG- ACRIN EAY131 Sub-Study I

Solid Tumor/Lymphoma

Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol I: EAY131-I: GDC-0032 (taselisib) in Patients with Tumors (other than breast cancer) with PIK3CA mutation but without KRAS mutation or PTEN loss

Record Created: 2016-03-02 16:49:42

ECOG- ACRIN EAY131 Sub-Study N

Solid Tumor/Lymphoma

Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol N: EAY131-N: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients with Tumors with PTEN Mutation or Deletion, with PTEN Expression on IHC

Record Created: 2016-03-02 16:50:47

ECOG- ACRIN EAY131 Sub-Study P

Solid Tumor/Lymphoma

Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol P: EAY131-P: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients with Tumors with PTEN Loss by IHC

Record Created: 2016-03-02 16:52:00

ECOG- ACRIN EAY131 Sub-Study Q

Solid Tumor/Lymphoma

Ado-trastuzumab Emtansine in Patients with Tumors with HER2 Amplification (Except Breast and Gastric/Gastro-Esophageal Junction (GEJ) Adenocarcinomas)

Record Created: 2015-08-18 15:13:45

ECOG- ACRIN EAY131 Sub-Study R

Solid Tumor/Lymphoma

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol R: Phase II Study of Trametinib in patients with BRAF fusions, or with non-V600E, nonV600K BRAF mutations

Record Created: 2015-06-18 14:00:15

ECOG- ACRIN EAY131 Sub-Study S1

Solid Tumor/Lymphoma

Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol S1: EAY131-S1: Phase II Study of Trametinib in Patients with Tumors with NF1 mutations

Record Created: 2016-03-02 16:53:48

ECOG- ACRIN EAY131 Sub-Study S2

Solid Tumor/Lymphoma

Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol S2: EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations

Record Created: 2016-03-02 16:54:38

ECOG- ACRIN EAY131 Sub-Study T

Solid Tumor/Lymphoma

GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations

Record Created: 2016-03-02 16:55:30

ECOG- ACRIN EAY131 Sub-Study U

Solid Tumor/Lymphoma

VS-6063 (defactinib) in Patients with Tumors with NF2 Loss

Record Created: 2015-08-18 15:14:49

ECOG- ACRIN EAY131 Sub-Study V

Solid Tumor/Lymphoma

Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)

Record Created: 2015-08-18 15:16:11

ECOG- ACRIN EAY131 Sub-Study W

Solid Tumor/Lymphoma

Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway

Record Created: 2016-06-08 11:23:47

ECOG- ACRIN EAY131 Sub-Study X

Solid Tumor/Lymphoma

Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol X: EAY131-X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations

Record Created: 2016-03-02 16:56:49

ECOG- ACRIN EAY131 Sub-Study Z1A

Solid Tumor/Lymphoma

Binimetinib in Patients with Tumors (Other than Melanoma) with NRAS Mutations

Record Created: 2016-06-08 11:25:07

ECOG- ACRIN EAY131 Sub-Study Z1B

Solid Tumor/Lymphoma

Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplifications and Rb Protein Expression by IHC

Record Created: 2016-06-08 11:26:43

ECOG- ACRIN EAY131 Sub-Study Z1D

Solid Tumor/Lymphoma

Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)

Record Created: 2016-06-08 11:27:52

ECOG-ACRIN EAY131 Master Protocol

Solid Tumor/Lymphoma

Molecular Analysis for Therapy Choice (MATCH)

Record Created: 2015-06-18 13:54:38

ECOG-ACRIN EAY131 Sub-Study A

Solid Tumor/Lymphoma

Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment

Record Created: 2015-08-18 15:04:32

Are you sure you would like to cancel?

All information will be lost.

Yes No ×

About the provider search

This search will provide you with WellSpan Medical Group and Northern Lancaster County (Ephrata) Medical Group primary care physicians and specialists. If we don’t have a WellSpan Medical Group physician to meet your criteria, the search will expand to include community physicians who partner with WellSpan Medical Group physicians through the WellSpan Provider Network or provide care to patients on the Medical Staffs of WellSpan’s Hospitals.

×

Schedule Your Next Appointment Online with MyWellSpan

Use your MyWellSpan patient portal any time to view available appointments, and pick the date and time that best suits your schedule.

Go to MyWellSpan

New to this practice?

If you don't have a WellSpan primary care provider and would like to schedule a new patient appointment with a provider who is accepting patients, just log into your MyWellSpan account, and go to the Appointment Center section. As you progress through the scheduling process, you will be able to see the offices that are accepting new patients in relation to your zip code. If you are not enrolled in MyWellSpan, go to https://my.wellspan.org, call 1-866-638-1842 or speak with a member of the staff at a participating facility to sign up. New patient scheduling not available at all practices/programs.

Already a patient at this practice?

If you already have a relationship with a WellSpan practice, simply log into your account, and go to the Appointment Center section. As you progress through the scheduling process, you will be able to schedule an appointment with any provider or practice that already counts you as a patient. Online scheduling varies by practice/program.

×